Neuropathic Pain - Pipeline Review, Q1 2011
Global Markets Direct’s, 'Neuropathic Pain - Pipeline Review, Q1 2011', provides an overview of the Neuropathic Pain therapeutic pipeline. This report provides information on the therapeutic development for Neuropathic Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Neuropathic Pain. 'Neuropathic Pain - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- A snapshot of the global therapeutic scenario for Neuropathic Pain.
- A review of the Neuropathic Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Neuropathic Pain pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Neuropathic Pain.
- Identify emerging players with potentially strong product portfolio and design
Neuropathic Pain – Pipeline Review, Q1 2011 Neuropathic Pain - Pipeline Review, Q1 2011 Reference Code: GMDHC023IDB Publication Date: February 2011 Neuropathic Pain – Pipeline Review, Q1 2011 GMDHC023IDB / Pub FEB 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(1) Neuropathic Pain – Pipeline Review, Q1 2011 Ta b le o f Co n te n ts Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 11 Global Markets Direct Report Coverage 11 Neuropathic Pain Overview 12 Therapeutics Development 13 An Overview of Pipeline Products for Neuropathic Pain 13 Neuropathic Pain Therapeutics under Development by Companies 15 Neuropathic Pain Therapeutics under Investigation by Universities/Institutes 20 Late Stage Products 23 Comparative Analysis 23 Mid Clinical Stage Products 24 Comparative Analysis 24 Early Clinical Stage Products 25 Comparative Analysis 25 Discovery and Pre-Clinical Stage Products 26 Comparative Analysis 26 Companies Involved in Neuropathic Pain Therapeutics Development 27 Bristol-Myers Squibb Company 27 Johnson & Johnson 27 Kyowa Hakko Kirin Co., Ltd. 28 Allergan, Inc. 28 NsGene A/S 30 Sanofi-Aventis 30 AstraZeneca PLC 31 Eli Lilly and Company 31 BioDelivery Sciences International, Inc. 32 GlaxoSmithKline plc 32 Nektar Therapeutics 34 Merck & Co., Inc. 34 Dainippon Sumitomo Pharma Co., Ltd. 35 Sangamo BioSciences, Inc. 35 Infinity Pharmaceuticals, Inc. 36 BioLineRx, Ltd. 36 Daewoong Pharmaceutical Co., Ltd. 37 Eisai Co., Ltd. 37 Gedeon Richter Plc. 38 Glenmark Pharmaceuticals Ltd. 38 King Pharmaceuticals, Inc. 39 Meda AB 39 Pfizer Inc. 40 UCB Group 40 Vernalis plc 42 EpiCept Corporation 42 Evotec Aktiengesellschaft 43 GW Pharmaceuticals plc 43 Neuropathic Pain – Pipeline Review, Q1 2011 GMDHC023IDB / Pub FEB 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(2) Neuropathic Pain – Pipeline Review, Q1 2011 Anavex Life Sciences Corp. 45 IntelGenx Technologies Corp. 45 AVANIR Pharmaceuticals 46 Lpath, Inc. 46 MediciNova, Inc. 47 Medivir AB 47 NeuroDiscovery Ltd 48 NeurogesX, Inc. 48 NicOx SA 49 NPS Pharmaceuticals, Inc. 49 Pharmos Corporation 50 Adolor Corp. 50 Torrent Pharmaceuticals Limited 51 Diamyd Medical AB 51 SCOLR Pharma, Inc. 52 DARA BioSciences, Inc. 52 Proximagen Neuroscience plc. 53 Newron Pharmaceuticals S.p.A. 53 Raptor Pharmaceuticals Corp. 55 Angelini Group 55 Auspex Pharmaceuticals 56 VistaGen Therapeutics , Inc. 56 Bionorica AG 57 Snowdon Inc. 57 Neurotune AG 58 Grunenthal GmbH 58 CREABILIS Therapeutics S.r.l. 59 Amura Holdings Ltd. 59 Affectis Pharmaceuticals AG 60 BioQuest Innovations Inc. 60 Grupo Uriach 61 Chlorion Pharma, Inc. 61 PharmEste 62 Solace Pharmaceuticals 62 Rottapharm SpA 63 Hydra Biosciences, Inc. 63 Yaupon Therapeutics, Inc. 64 NeurAxon, Inc. 64 Virobay Inc. 65 QRxPharma Limited 65 Cara Therapeutics, Inc. 66 Kalypsys, Inc. 66 Bial Group 67 Krenitsky Pharmaceuticals Inc. 67 Lectus Therapeutics Limited 68 KAI Pharmaceuticals Inc. 68 Winston Pharmaceuticals, Inc. 69 Bial - Portela & Ca, S.A. 69 Neuropathic Pain – Pipeline Review, Q1 2011 GMDHC023IDB / Pub FEB 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(3) Neuropathic Pain – Pipeline Review, Q1 2011 TheraQuest Biosciences, LLC 70 Celtic Pharmaceutical Holdings L.P. 70 RaQualia Pharma Inc. 71 SK Bio-Pharmaceuticals 71 BUNKER INDUSTRIA FARMACEUTICA LTDA. 72 Universities/Institutes Involved in Neuropathic Pain Therapeutics Development 73 Neuropathic Pain - Therapeutics Assessment 76 Assessment by Monotherapy Products 76 Assessment by Combination Products 77 Assessment by Route of Administration 78 Assessment by Molecule Type 81 Late Stage Drug Profiles – Companies 83 BEMA Buprenorphine - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 Dronabinol - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 Lyrica - Drug Profile 85 Product Description 85 Mechanism of Action 85 R&D Progress 85 Sativex - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Stedesa - Drug Profile 88 Product Description 88 Mechanism of Action 88 R&D Progress 88 Vitatonus Dexa - Drug Profile 89 Product Description 89 Mechanism of Action 89 R&D Progress 89 Zenvia - Drug Profile 90 Product Description 90 Mechanism of Action 90 R&D Progress 90 Late Stage Drug Profiles – Universities/Institutes 91 Amitriptyline - Drug Profile 91 Product Description 91 Mechanism of Action 91 R&D Progress 91 Amitriptyline + Ketamine + Lidocaine - Drug Profile 92 Product Description 92 Mechanism of Action 92 Neuropathic Pain – Pipeline Review, Q1 2011 GMDHC023IDB / Pub FEB 2011 © Global Markets Direct. This report is a licensed product and is not to be photocopied Page(4) Neuropathic Pain – Pipeline Review, Q1 2011 R&D Progress 92 Hypothetica - Drug Profile 93 Product Description 93 Mechanism of Action 93 R&D Progress 93 ketamine - Drug Profile 94 Product Description 94 Mechanism of Action 94
Pages to are hidden for
"Neuropathic Pain - Pipeline Review, Q1 2011"Please download to view full document